127 related articles for article (PubMed ID: 17926092)
1. Using IFN-gamma as a biomarker for detecting exposure to viral pathogens.
Li L; Dufour AP
Curr Microbiol; 2008 Jan; 56(1):84-8. PubMed ID: 17926092
[TBL] [Abstract][Full Text] [Related]
2. Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.
Henke A; Zell R; Ehrlich G; Stelzner A
J Virol; 2001 Sep; 75(17):8187-94. PubMed ID: 11483764
[TBL] [Abstract][Full Text] [Related]
3. Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis.
Gauntt CJ; Paque RE; Trousdale MD; Gudvangen RJ; Barr DT; Lipotich GJ; Nealon TJ; Duffey PS
Infect Immun; 1983 Feb; 39(2):851-64. PubMed ID: 6299950
[TBL] [Abstract][Full Text] [Related]
4. Sex Hormone Contributes to Sexually Dimorphic Susceptibility in CVB3-Induced Viral Myocarditis via Modulating IFN-γ
Zhou N; Yue Y; Xiong S
Can J Cardiol; 2018 Apr; 34(4):492-501. PubMed ID: 29455951
[TBL] [Abstract][Full Text] [Related]
5. Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon.
Chehadeh W; Lobert PE; Sauter P; Goffard A; Lucas B; Weill J; Vantyghem MC; Alm G; Pigny P; Hober D
J Virol; 2005 Nov; 79(22):13882-91. PubMed ID: 16254324
[TBL] [Abstract][Full Text] [Related]
6. IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-gamma and macrophage and neutrophil populations in the heart.
Fairweather D; Frisancho-Kiss S; Yusung SA; Barrett MA; Davis SE; Steele RA; Gatewood SJ; Rose NR
J Immunol; 2005 Jan; 174(1):261-9. PubMed ID: 15611248
[TBL] [Abstract][Full Text] [Related]
7. Interferon-beta expression and type I interferon receptor signaling of hepatocytes prevent hepatic necrosis and virus dissemination in Coxsackievirus B3-infected mice.
Koestner W; Spanier J; Klause T; Tegtmeyer PK; Becker J; Herder V; Borst K; Todt D; Lienenklaus S; Gerhauser I; Detje CN; Geffers R; Langereis MA; Vondran FWR; Yuan Q; van Kuppeveld FJM; Ott M; Staeheli P; Steinmann E; Baumgärtner W; Wacker F; Kalinke U
PLoS Pathog; 2018 Aug; 14(8):e1007235. PubMed ID: 30075026
[TBL] [Abstract][Full Text] [Related]
8. Diabetes acceleration or prevention by a coxsackievirus B4 infection: critical requirements for both interleukin-4 and gamma interferon.
Serreze DV; Wasserfall C; Ottendorfer EW; Stalvey M; Pierce MA; Gauntt C; O'Donnell B; Flanagan JB; Campbell-Thompson M; Ellis TM; Atkinson MA
J Virol; 2005 Jan; 79(2):1045-52. PubMed ID: 15613333
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma-induced activation of nitric oxide-mediated antiviral activity of macrophages caused by a recombinant coxsackievirus B3.
Jarasch N; Martin U; Kamphausen E; Zell R; Wutzler P; Henke A
Viral Immunol; 2005; 18(2):355-64. PubMed ID: 16035947
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the T-cell response to coxsackievirus B4: evidence that effector memory cells predominate in patients with type 1 diabetes.
Varela-Calvino R; Ellis R; Sgarbi G; Dayan CM; Peakman M
Diabetes; 2002 Jun; 51(6):1745-53. PubMed ID: 12031961
[TBL] [Abstract][Full Text] [Related]
11. AIM2 Co-immunization with VP1 Is Associated with Increased Memory CD8 T Cells and Mounts Long Lasting Protection against Coxsackievirus B3 Challenge.
Yin L; Chai D; Yue Y; Dong C; Xiong S
Front Cell Infect Microbiol; 2017; 7():247. PubMed ID: 28642849
[TBL] [Abstract][Full Text] [Related]
12. Exogenous interleukin-12 protects against lethal infection with coxsackievirus B4.
Potvin DM; Metzger DW; Lee WT; Collins DN; Ramsingh AI
J Virol; 2003 Aug; 77(15):8272-9. PubMed ID: 12857896
[TBL] [Abstract][Full Text] [Related]
13. Yakammaoto inhibited human coxsackievirus B4 (CVB4)-induced airway and renal tubular injuries by preventing viral attachment, internalization, and replication.
Yen MH; Lee JJ; Yeh CF; Wang KC; Chiang YW; Chiang LC; Chang JS
J Ethnopharmacol; 2014 Feb; 151(3):1056-1063. PubMed ID: 24361333
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of IL-2 inducible T-cell kinase alleviates T-cell activation and murine myocardial inflammation associated with CVB3 infection.
He F; Yao H; Xiao Z; Han J; Zou J; Liu Z
Mol Immunol; 2014 May; 59(1):30-8. PubMed ID: 24462896
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the protective capability of a recombinant coxsackievirus B3 variant expressing interferon-gamma.
Henke A; Jarasch N; Martin U; Zell R; Wutzler P
Viral Immunol; 2008 Mar; 21(1):38-48. PubMed ID: 18355121
[TBL] [Abstract][Full Text] [Related]
16. Preexposure to PM2.5 exacerbates acute viral myocarditis associated with Th17 cell.
Xie Y; Zhang X; Tian Z; Jiang R; Chen R; Song W; Zhao J
Int J Cardiol; 2013 Oct; 168(4):3837-45. PubMed ID: 23849969
[TBL] [Abstract][Full Text] [Related]
17. Mapping of a neutralizing antigenic site of Coxsackievirus B4 by construction of an antigen chimera.
Reimann BY; Zell R; Kandolf R
J Virol; 1991 Jul; 65(7):3475-80. PubMed ID: 1645779
[TBL] [Abstract][Full Text] [Related]
18. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.
Slifka MK; Pagarigan R; Mena I; Feuer R; Whitton JL
J Virol; 2001 Mar; 75(5):2377-87. PubMed ID: 11160741
[TBL] [Abstract][Full Text] [Related]
19. Astragaloside IV exerts antiviral effects against coxsackievirus B3 by upregulating interferon-gamma.
Zhang Y; Zhu H; Huang C; Cui X; Gao Y; Huang Y; Gong W; Zhao Y; Guo S
J Cardiovasc Pharmacol; 2006 Feb; 47(2):190-5. PubMed ID: 16495755
[TBL] [Abstract][Full Text] [Related]
20. TRIM21 Restricts Coxsackievirus B3 Replication, Cardiac and Pancreatic Injury via Interacting With MAVS and Positively Regulating IRF3-Mediated Type-I Interferon Production.
Liu H; Li M; Song Y; Xu W
Front Immunol; 2018; 9():2479. PubMed ID: 30410495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
